Join to View Full Profile
1275 York AveDepartment of Medicine Box 8New York, NY 10065
Phone+1 212-639-2282
Dr. Guha is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2003 - 2006
All India Institute of Medical SciencesClass of 1995
Certifications & Licensure
NY State Medical License 2008 - 2025
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase I Study of MGAH22 in Patients With Refractory HER2 Positive Cancers Start of enrollment: 2010 Aug 01
- Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Start of enrollment: 2011 Feb 08
- Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib Start of enrollment: 2016 Apr 13
Publications & Presentations
PubMed
- 6 citationsMicroenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities.Parth Desai, Nobuyuki Takahashi, Rajesh Kumar, Samantha Nichols, Justin Malin
Cell Reports. Medicine. 2024-06-18 - 1 citationsFunctional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer.Nitin Roper, Rajaa El Meskini, Tapan Maity, Devon Atkinson, Amanda Day
Cancer Research Communications. 2024-02-08 - 26 citationsThe role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.Deborah R Caswell, Philippe Gui, Manasi K Mayekar, Emily K Law, Oriol Pich
Nature Genetics. 2024-01-01
Press Mentions
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024September 16th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
